HUP0204562A2 - Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények - Google Patents

Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények

Info

Publication number
HUP0204562A2
HUP0204562A2 HU0204562A HUP0204562A HUP0204562A2 HU P0204562 A2 HUP0204562 A2 HU P0204562A2 HU 0204562 A HU0204562 A HU 0204562A HU P0204562 A HUP0204562 A HU P0204562A HU P0204562 A2 HUP0204562 A2 HU P0204562A2
Authority
HU
Hungary
Prior art keywords
camptothecin
polyglutamic acid
formula
preparation
methods
Prior art date
Application number
HU0204562A
Other languages
English (en)
Inventor
Rama Bhatt
J. Peter Klein
Robert A. Lewis
Jack W. Singer
John Tulinsky
Peter Vries
Original Assignee
Cell Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics, Inc. filed Critical Cell Therapeutics, Inc.
Publication of HUP0204562A2 publication Critical patent/HUP0204562A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Abstract

A találmány tárgya kompozíció, amely (I) általános képletűpoliglutaminsav kamptotecin konjugátumból áll, ahol a képletben PGjelentése poliglutaminsav polimer; X jelentése egyes kötés, -[OC-(CHR')p-NH]n- általános képletű aminoacil kapcsolócsoport vagy -[OC-(CHR')p-O]n- általános képletű hidroxiacil kapcsolócsoport, ahol R'jelentése egy természetes aminosav oldallánca; Kamptotecin jelentése20(S)-kamptotecin vagy biológiailag aktív 20(S)-kamptotecin-analóg; mjelentése 5-től 65-ig terjedő pozitív egész szám; Kamptotecin-Xkovalensen kötődik az említett polimer karboxilcsoportjához egyészter- vagy amidkötésen keresztül; n jelentése 1-től 10-igterjedő egész szám; és p jelentése 1-től 10-ig terjedő egészszám. A találmány tárgyát képezi továbbá a fenti konjugátumokelőállítási eljárása, és a konjugátumokat tartalmazó gyógyászatikészítmények, amelyek alkalmasak daganatos és leukémiás megbetegedésekkezelésére. Ó
HU0204562A 2000-03-17 2001-03-19 Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények HUP0204562A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19042900P 2000-03-17 2000-03-17
PCT/US2001/008553 WO2001070275A2 (en) 2000-03-17 2001-03-19 Polyglutamic acid-camptothecin conjugates and methods of preparation

Publications (1)

Publication Number Publication Date
HUP0204562A2 true HUP0204562A2 (hu) 2003-04-28

Family

ID=22701317

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204562A HUP0204562A2 (hu) 2000-03-17 2001-03-19 Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények

Country Status (20)

Country Link
US (1) US20020016285A1 (hu)
EP (1) EP1267939A2 (hu)
JP (1) JP2003527443A (hu)
KR (1) KR20020082888A (hu)
CN (1) CN1429121A (hu)
AU (1) AU2001247513A1 (hu)
BR (1) BR0109272A (hu)
CA (1) CA2402643A1 (hu)
CZ (1) CZ20023330A3 (hu)
HU (1) HUP0204562A2 (hu)
IL (1) IL151685A0 (hu)
MX (1) MXPA02009082A (hu)
NO (1) NO20024421L (hu)
PL (1) PL358335A1 (hu)
RU (1) RU2002128610A (hu)
SI (1) SI21172A (hu)
SK (1) SK14822002A3 (hu)
TR (1) TR200202194T2 (hu)
WO (1) WO2001070275A2 (hu)
ZA (1) ZA200207423B (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JP2003511423A (ja) 1999-10-12 2003-03-25 セル・セラピューティックス・インコーポレーテッド ポリグルタメート−治療薬コンジュゲートの製造
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
DE60331537D1 (de) * 2002-05-17 2010-04-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
JP4745664B2 (ja) * 2002-10-31 2011-08-10 日本化薬株式会社 カンプトテシン類の高分子誘導体
US8017762B2 (en) * 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
US7851615B2 (en) * 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US8796436B2 (en) 2003-04-17 2014-08-05 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP2666858A1 (en) * 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Modified iRNA agents
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006020722A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EP1792927B1 (en) 2004-09-22 2013-03-06 Nippon Kayaku Kabushiki Kaisha Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
KR20080039344A (ko) 2005-07-14 2008-05-07 웰스테트 바이올로직스 코포레이션 바이러스, 플루오로피리미딘 및 캄토테신을 이용한 암치료방법
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
DK1969031T3 (da) * 2005-12-05 2009-09-14 Nitto Denko Corp Polyglutamat-aminosyre-konjugater og fremgangsmåder
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
WO2007111211A1 (ja) 2006-03-28 2007-10-04 Nippon Kayaku Kabushiki Kaisha タキサン類の高分子結合体
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
RU2447095C2 (ru) 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2008041610A1 (fr) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha Mélange d'un dérivé de résorcinol avec un polymère
JP5503872B2 (ja) 2006-11-06 2014-05-28 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
WO2008056654A1 (en) * 2006-11-08 2008-05-15 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
EP2109448B1 (en) * 2007-02-09 2013-09-11 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CA2685739C (en) 2007-04-30 2016-06-14 Arqule, Inc Hydroxy sulfonate of quinone compounds and their uses
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
JP2010526917A (ja) * 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
JP5341879B2 (ja) 2007-05-09 2013-11-13 日東電工株式会社 疎水性化合物及びポリアミノ酸複合体を含む組成物
CN101808651B (zh) 2007-09-28 2013-03-27 日本化药株式会社 类固醇类的高分子结合物
JP2011513412A (ja) * 2008-03-06 2011-04-28 日東電工株式会社 ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
CN101977631A (zh) 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
US9149540B2 (en) 2008-05-08 2015-10-06 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of folic acid or folic acid derivative
JP2011162569A (ja) 2008-05-23 2011-08-25 Nano Career Kk カンプトテシン高分子誘導体及びその用途
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
JP2012505906A (ja) * 2008-10-15 2012-03-08 日東電工株式会社 ポリグルタメートコンジュゲートの調製方法
BRPI0919842A8 (pt) * 2008-10-21 2015-09-22 Enzon Pharmaceuticals Inc tratamento de neuroblastioma com conjugados poliméricos de múltiplos braços de 7-etil-10-hidroxicamptotecina
EP2431403B1 (en) 2009-05-15 2016-09-28 Nipponkayaku Kabushikikaisha Polymer conjugate of bioactive substance having hydroxy group
BR112012013305A2 (pt) * 2009-12-16 2016-03-01 Nitto Denko Corp processos para a preparação de ácido poliglutâmico
BR112012022337A2 (pt) * 2010-03-11 2016-07-05 Nitto Denko Corp composição e respectivos método de preparação e uso de quantidade eficaz
WO2012067138A1 (ja) 2010-11-17 2012-05-24 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
CN102649810A (zh) * 2011-05-19 2012-08-29 东北林业大学 喜树碱衍生物、其制备方法和用途
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
US9180203B2 (en) * 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
SI3182996T1 (sl) 2014-08-22 2023-04-28 Celgene Corporation Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
JP2018527302A (ja) 2015-06-26 2018-09-20 セルジーン コーポレイション 免疫調節化合物を用いたカポジ肉腫またはｋｓｈｖ誘発性リンパ腫の治療方法、及びバイオマーカーの使用
CN106267227A (zh) * 2016-08-12 2017-01-04 北京蓝贝望生物医药科技股份有限公司 抗肿瘤药物
CN110177566A (zh) * 2016-09-30 2019-08-27 伊夫7治疗公司 用于制备靶向肿瘤-脉管系统的抗肿瘤剂的方法
CN106831853B (zh) * 2017-02-15 2019-02-22 浙江海正药业股份有限公司 7-乙基-10-o-叔丁基二苯基硅基喜树碱-20-o-甘氨酸盐酸盐的制备工艺
CN108727581A (zh) * 2017-04-18 2018-11-02 华东师范大学 以苯硼酸酯为连接单元的两亲性喜树碱高分子前药及其制备方法和应用
JP2021095424A (ja) * 2018-03-28 2021-06-24 持田製薬株式会社 抗癌剤結合アルギン酸誘導体
CN115298189A (zh) 2019-12-04 2022-11-04 丹塔里股份有限公司 合成治疗性纳米颗粒的方法和组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
EA002400B1 (ru) * 1996-03-12 2002-04-25 Пи Джи-Ти Экс Эл Компани, Л.П. Водорастворимые пролекарства противоракового действия
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives

Also Published As

Publication number Publication date
ZA200207423B (en) 2003-12-17
NO20024421L (no) 2002-11-15
SI21172A (sl) 2003-10-31
CZ20023330A3 (cs) 2003-02-12
BR0109272A (pt) 2004-06-29
EP1267939A2 (en) 2003-01-02
WO2001070275A3 (en) 2002-01-03
IL151685A0 (en) 2003-04-10
RU2002128610A (ru) 2004-03-27
NO20024421D0 (no) 2002-09-16
WO2001070275A2 (en) 2001-09-27
JP2003527443A (ja) 2003-09-16
PL358335A1 (en) 2004-08-09
CN1429121A (zh) 2003-07-09
CA2402643A1 (en) 2001-09-27
US20020016285A1 (en) 2002-02-07
AU2001247513A1 (en) 2001-10-03
KR20020082888A (ko) 2002-10-31
MXPA02009082A (es) 2003-12-11
TR200202194T2 (tr) 2003-01-21
SK14822002A3 (sk) 2003-05-02

Similar Documents

Publication Publication Date Title
HUP0204562A2 (hu) Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
AU2003280592B2 (en) High-molecular weight derivatives of camptothecins
AU725195B2 (en) Interferon conjugates
HUP0100507A2 (hu) Polietilén-glikol-GRF konjugátumok, eljárás azok helyspecifikus előállítására, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
RU2149646C1 (ru) Полимерный конъюгат, фармацевтическая композиция
EP2109448B1 (en) Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
MX2009002857A (es) Enlazadores polimericos basados en lisina.
US20020058611A1 (en) Carrier for in vivo delivery of a therapeutic agent
CA2145502A1 (en) Alginate-bioactive agent conjugates
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
MX2009002853A (es) Tratamiento de linfomas no hodgkin con conjugados polimericos de multibrazo de 7-etil-10-hidroxicamptotecina.
IL139285A0 (en) Peg-lhrh analog conjugates, their preparation and use
KR20170075724A (ko) 접합체 및 접합 시약
KR20100051722A (ko) 피리딜 이황화 부분을 포함하는 폴리머 링커
TW200810757A (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
JP7069043B2 (ja) コンジュゲート及びコンジュゲート試薬
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
EP1279405A1 (en) Drugs retained in target tissue over long time
WO2002043663A2 (en) Tetrapartate prodrugs
HUP0203899A2 (hu) Alfavbéta3 vagy alfavbéta5 integrin antagonistát és citosztatikumot tartalmazó konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
WO2020072681A1 (en) Aromatic ring substituted amphiphilic polymers as drug delivery systems
EP3442595A1 (en) Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring